ASSESSMENT OF EFFICIENCY OF DIFFERENT PLASMA DERIVED FVIII CONCENTRATES IN BLEEDING CONTROL - HEMOPHILIA PATIENTS? PERSPECTIVE
(Abstract release date: 05/21/15)
EHA Library. Bodrozic J. 06/12/15; 103011; PB1696
Disclosure(s): Clinical Center Of Serbia, BelgradeClinic of hematology
Mrs. Jelena Bodrozic
Contributions
Contributions
Abstract
Abstract: PB1696
Type: Publication Only
Background
Patients in Serbia are usually switching between different plasma derived FVIII concentrates (pdFVIII), dependent on their market availability. We observed that some of the patients expressed a personal impression that there is a difference in efficiency of different factor concentrates in achievement of bleeding control.
Aims
To investigate is there any difference regarding efficiency in achievement bleeding control in hemophilia A patients between different pdFVIII concentrates, based on analysis of subjective assessments recorded in patients diaries
Methods
We extracted the data from a personal patient diary of eight adult patients, average age of 29, with severe form of hemophilia A about spontaneous joint bleeding episodes, while they were on a low dosage tertiary prophylaxis. Over a 4-year observation period from January 2010 to March 2014, our patients received, twice a week, the same dosage (15U/kg) of pdFVIII. During this time they switched between five different pdFVIII, dependent on the availability at that specific point of time. For every bleeding episode we recorded the type of pdFVIII applied, pain intensity, graded from 1 to 10, time necessary for the bleeding to stop measured in hours and overall subjective assessment of the therapy efficiency (OSA). OSA was graded from 1, meaning that patient considered therapy completely ineffective, to 10, meaning that bleeding stopped immediately after treatment.
Results
Eight patients received first plasma derived FVIII concentrate (pdFVIII1) during altogether 88 months, second (pdFVIII2) 83 months, third (pdFVIII3) 68, fourth (pdFVIII4) 79 and fifth (pdFVIII5) during 82 months. For pdFVIII1 average bleeding frequency per month was 0.53, for pdFVIII2 0.52, pdFVIII3 0.52, pdFVIII4 0.59, pdFVIII5 0.58. Mean time for bleeding to stop while using different pdFVIII was 6.15, 5.88, 6.08, 5.91, 6,02 hours. Average OSA was 6.0, 7.38, 6.67, 6.0, 6.9, for each pdFVIII respectively. In multivariate logistic regression analysis, OSA, was highly influenced by the time necessary for the bleeding to stop (OR=0,108 CI 0,068-0,147), but not with used pdFVIII concentrate.
Summary
According to our results, the type of pdFVIII applied didn’t have any influence on OSA as well as the pain intensity. The OSA was dependent only on the length of bleeding episode.
Keyword(s): Coagulation factors, Hemophilia A
Session topic: Publication Only
Type: Publication Only
Background
Patients in Serbia are usually switching between different plasma derived FVIII concentrates (pdFVIII), dependent on their market availability. We observed that some of the patients expressed a personal impression that there is a difference in efficiency of different factor concentrates in achievement of bleeding control.
Aims
To investigate is there any difference regarding efficiency in achievement bleeding control in hemophilia A patients between different pdFVIII concentrates, based on analysis of subjective assessments recorded in patients diaries
Methods
We extracted the data from a personal patient diary of eight adult patients, average age of 29, with severe form of hemophilia A about spontaneous joint bleeding episodes, while they were on a low dosage tertiary prophylaxis. Over a 4-year observation period from January 2010 to March 2014, our patients received, twice a week, the same dosage (15U/kg) of pdFVIII. During this time they switched between five different pdFVIII, dependent on the availability at that specific point of time. For every bleeding episode we recorded the type of pdFVIII applied, pain intensity, graded from 1 to 10, time necessary for the bleeding to stop measured in hours and overall subjective assessment of the therapy efficiency (OSA). OSA was graded from 1, meaning that patient considered therapy completely ineffective, to 10, meaning that bleeding stopped immediately after treatment.
Results
Eight patients received first plasma derived FVIII concentrate (pdFVIII1) during altogether 88 months, second (pdFVIII2) 83 months, third (pdFVIII3) 68, fourth (pdFVIII4) 79 and fifth (pdFVIII5) during 82 months. For pdFVIII1 average bleeding frequency per month was 0.53, for pdFVIII2 0.52, pdFVIII3 0.52, pdFVIII4 0.59, pdFVIII5 0.58. Mean time for bleeding to stop while using different pdFVIII was 6.15, 5.88, 6.08, 5.91, 6,02 hours. Average OSA was 6.0, 7.38, 6.67, 6.0, 6.9, for each pdFVIII respectively. In multivariate logistic regression analysis, OSA, was highly influenced by the time necessary for the bleeding to stop (OR=0,108 CI 0,068-0,147), but not with used pdFVIII concentrate.
Summary
According to our results, the type of pdFVIII applied didn’t have any influence on OSA as well as the pain intensity. The OSA was dependent only on the length of bleeding episode.
Keyword(s): Coagulation factors, Hemophilia A
Session topic: Publication Only
Abstract: PB1696
Type: Publication Only
Background
Patients in Serbia are usually switching between different plasma derived FVIII concentrates (pdFVIII), dependent on their market availability. We observed that some of the patients expressed a personal impression that there is a difference in efficiency of different factor concentrates in achievement of bleeding control.
Aims
To investigate is there any difference regarding efficiency in achievement bleeding control in hemophilia A patients between different pdFVIII concentrates, based on analysis of subjective assessments recorded in patients diaries
Methods
We extracted the data from a personal patient diary of eight adult patients, average age of 29, with severe form of hemophilia A about spontaneous joint bleeding episodes, while they were on a low dosage tertiary prophylaxis. Over a 4-year observation period from January 2010 to March 2014, our patients received, twice a week, the same dosage (15U/kg) of pdFVIII. During this time they switched between five different pdFVIII, dependent on the availability at that specific point of time. For every bleeding episode we recorded the type of pdFVIII applied, pain intensity, graded from 1 to 10, time necessary for the bleeding to stop measured in hours and overall subjective assessment of the therapy efficiency (OSA). OSA was graded from 1, meaning that patient considered therapy completely ineffective, to 10, meaning that bleeding stopped immediately after treatment.
Results
Eight patients received first plasma derived FVIII concentrate (pdFVIII1) during altogether 88 months, second (pdFVIII2) 83 months, third (pdFVIII3) 68, fourth (pdFVIII4) 79 and fifth (pdFVIII5) during 82 months. For pdFVIII1 average bleeding frequency per month was 0.53, for pdFVIII2 0.52, pdFVIII3 0.52, pdFVIII4 0.59, pdFVIII5 0.58. Mean time for bleeding to stop while using different pdFVIII was 6.15, 5.88, 6.08, 5.91, 6,02 hours. Average OSA was 6.0, 7.38, 6.67, 6.0, 6.9, for each pdFVIII respectively. In multivariate logistic regression analysis, OSA, was highly influenced by the time necessary for the bleeding to stop (OR=0,108 CI 0,068-0,147), but not with used pdFVIII concentrate.
Summary
According to our results, the type of pdFVIII applied didn’t have any influence on OSA as well as the pain intensity. The OSA was dependent only on the length of bleeding episode.
Keyword(s): Coagulation factors, Hemophilia A
Session topic: Publication Only
Type: Publication Only
Background
Patients in Serbia are usually switching between different plasma derived FVIII concentrates (pdFVIII), dependent on their market availability. We observed that some of the patients expressed a personal impression that there is a difference in efficiency of different factor concentrates in achievement of bleeding control.
Aims
To investigate is there any difference regarding efficiency in achievement bleeding control in hemophilia A patients between different pdFVIII concentrates, based on analysis of subjective assessments recorded in patients diaries
Methods
We extracted the data from a personal patient diary of eight adult patients, average age of 29, with severe form of hemophilia A about spontaneous joint bleeding episodes, while they were on a low dosage tertiary prophylaxis. Over a 4-year observation period from January 2010 to March 2014, our patients received, twice a week, the same dosage (15U/kg) of pdFVIII. During this time they switched between five different pdFVIII, dependent on the availability at that specific point of time. For every bleeding episode we recorded the type of pdFVIII applied, pain intensity, graded from 1 to 10, time necessary for the bleeding to stop measured in hours and overall subjective assessment of the therapy efficiency (OSA). OSA was graded from 1, meaning that patient considered therapy completely ineffective, to 10, meaning that bleeding stopped immediately after treatment.
Results
Eight patients received first plasma derived FVIII concentrate (pdFVIII1) during altogether 88 months, second (pdFVIII2) 83 months, third (pdFVIII3) 68, fourth (pdFVIII4) 79 and fifth (pdFVIII5) during 82 months. For pdFVIII1 average bleeding frequency per month was 0.53, for pdFVIII2 0.52, pdFVIII3 0.52, pdFVIII4 0.59, pdFVIII5 0.58. Mean time for bleeding to stop while using different pdFVIII was 6.15, 5.88, 6.08, 5.91, 6,02 hours. Average OSA was 6.0, 7.38, 6.67, 6.0, 6.9, for each pdFVIII respectively. In multivariate logistic regression analysis, OSA, was highly influenced by the time necessary for the bleeding to stop (OR=0,108 CI 0,068-0,147), but not with used pdFVIII concentrate.
Summary
According to our results, the type of pdFVIII applied didn’t have any influence on OSA as well as the pain intensity. The OSA was dependent only on the length of bleeding episode.
Keyword(s): Coagulation factors, Hemophilia A
Session topic: Publication Only
{{ help_message }}
{{filter}}